middle.news
Argent BioPharma Advances CannEpil® into US Veterinary Market with FDA Pathway
9:14am on Thursday 6th of August, 2026 AEST
•
Pharmaceuticals
Read Story
Argent BioPharma Advances CannEpil® into US Veterinary Market with FDA Pathway
9:14am on Thursday 6th of August, 2026 AEST
Key Points
Splash Beverage initiates US veterinary development for CannEpil®
Lupvindol Biosciences to lead FDA regulatory and pharmaceutical strategy
Focus on canine oncology and chronic pain management
Program navigates FDA Center for Veterinary Medicine approval pathways
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE